Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
1.
BMC Cancer ; 24(1): 951, 2024 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-39097719

RESUMEN

BACKGROUND: Tobacco use is one of the main risk factors for Lung Cancer (LC) development. However, about 10-20% of those diagnosed with the disease are never-smokers. For Non-Small Cell Lung Cancer (NSCLC) there are clear differences in both the clinical presentation and the tumor genomic profiles between smokers and never-smokers. For example, the Lung Adenocarcinoma (LUAD) histological subtype in never-smokers is predominately found in young women of European, North American, and Asian descent. While the clinical presentation and tumor genomic profiles of smokers have been widely examined, never-smokers are usually underrepresented, especially those of a Latin American (LA) background. In this work, we characterize, for the first time, the difference in the genomic profiles between smokers and never-smokers LC patients from Chile. METHODS: We conduct a comparison by smoking status in the frequencies of genomic alterations (GAs) including somatic mutations and structural variants (fusions) in a total of 10 clinically relevant genes, including the eight most common actionable genes for LC (EGFR, KRAS, ALK, MET, BRAF, RET, ERBB2, and ROS1) and two established driver genes for malignancies other than LC (PIK3CA and MAP2K1). Study participants were grouped as either smokers (current and former, n = 473) or never-smokers (n = 200) according to self-report tobacco use at enrollment. RESULTS: Our findings indicate a higher overall GA frequency for never-smokers compared to smokers (58 vs. 45.7, p-value < 0.01) with the genes EGFR, KRAS, and PIK3CA displaying the highest prevalence while ERBB2, RET, and ROS1 the lowest. Never-smokers present higher frequencies in seven out of the 10 genes; however, smokers harbor a more complex genomic profile. The clearest differences between groups are seen for EGFR (15.6 vs. 21.5, p-value: < 0.01), PIK3CA (6.8 vs 9.5) and ALK (3.2 vs 7.5) in favor of never-smokers, and KRAS (16.3 vs. 11.5) and MAP2K1 (6.6 vs. 3.5) in favor of smokers. Alterations in these genes are comprised almost exclusively by somatic mutations in EGFR and mainly by fusions in ALK, and only by mutations in PIK3CA, KRAS and MAP2K1. CONCLUSIONS: We found clear differences in the genomic landscape by smoking status in LUAD patients from Chile, with potential implications for clinical management in these limited-resource settings.


Asunto(s)
Neoplasias Pulmonares , No Fumadores , Fumadores , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/epidemiología , Neoplasias Pulmonares/etiología , Femenino , Masculino , Fumadores/estadística & datos numéricos , Persona de Mediana Edad , No Fumadores/estadística & datos numéricos , Anciano , Fumar/genética , Fumar/efectos adversos , Fumar/epidemiología , Mutación , Genómica/métodos , Adulto , Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/epidemiología , Carcinoma de Pulmón de Células no Pequeñas/patología
2.
Rev. Nac. (Itauguá) ; 15(2)dic. 2023.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1529483

RESUMEN

Reportamos el caso clínico de un lactante menor con una presentación anular de hemangioma, que nos plantea dudas en su clasificación. Se precisan los diagnósticos diferenciales y la necesidad de la determinación del marcador GLUT 1 en hospitales públicos.


We report the clinical case of a young infant with an annular presentation of hemangioma, which raises doubts regarding its classification. Differential diagnoses and the need to determine the GLUT 1 marker in public hospitals are specified.

3.
Rev. Nac. (Itauguá) ; 15(2): 97, dic.2023.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1532935

RESUMEN

Reportamos el caso clínico de un lactante menor con una presentación anular de hemangioma, que nos plantea dudas en su clasificación. Se precisan los diagnósticos diferenciales y la necesidad de la determinación del marcador GLUT 1 en hospitales públicos.


We report the clinical case of a young infant with an annular presentation of hemangioma, which raises doubts regarding its classification. Differential diagnoses and the need to determine the GLUT 1 marker in public hospitals are specified.

4.
Int J Mol Sci ; 23(23)2022 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-36499015

RESUMEN

Cancer is primarily a disease in which late diagnosis is linked to poor prognosis, and unfortunately, detection and management are still challenging. Circulating tumor cells (CTCs) are a potential resource to address this disease. Cell fusion, an event discovered recently in CTCs expressing carcinoma and leukocyte markers, occurs when ≥2 cells become a single entity (hybrid cell) after the merging of their plasma membranes. Cell fusion is still poorly understood despite continuous evaluations in in vitro/in vivo studies. Blood samples from 14 patients with high-grade serous ovarian cancer (A.C. Camargo Cancer Center, São Paulo, Brazil) were collected with the aim to analyze the CTCs/hybrid cells and their correlation to clinical outcome. The EDTA collected blood (6 mL) from patients was used to isolate/identify CTCs/hybrid cells by ISET. We used markers with possible correlation with the phenomenon of cell fusion, such as MC1-R, EpCAM and CD45, as well as CEN8 expression by CISH analysis. Samples were collected at three timepoints: baseline, after one month (first follow-up) and after three months (second follow-up) of treatment with olaparib (total sample = 38). Fourteen patients were included and in baseline and first follow-up all patients showed at least one CTC. We found expression of MC1-R, EpCAM and CD45 in cells (hybrid) in at least one of the collection moments. Membrane staining with CD45 was found in CTCs from the other cohort, from the other center, evaluated by the CellSearch® system. The presence of circulating tumor microemboli (CTM) in the first follow-up was associated with a poor recurrence-free survival (RFS) (5.2 vs. 12.2 months; p = 0.005). The MC1-R expression in CTM in the first and second follow-ups was associated with a shorter RFS (p = 0.005). CEN8 expression in CTCs was also related to shorter RFS (p = 0.035). Our study identified a high prevalence of CTCs in ovarian cancer patients, as well as hybrid cells. Both cell subtypes demonstrate utility in prognosis and in the assessment of response to treatment. In addition, the expression of MC1-R and EpCAM in hybrid cells brings new perspectives as a possible marker for this phenomenon in ovarian cancer.


Asunto(s)
Cistadenocarcinoma Seroso , Células Neoplásicas Circulantes , Neoplasias Ováricas , Femenino , Humanos , Células Neoplásicas Circulantes/patología , Biomarcadores de Tumor/metabolismo , Brasil
6.
Front Oncol ; 12: 809441, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35392220

RESUMEN

The clinical and pathological responses to multimodal neoadjuvant therapy in locally advanced rectal cancers (LARCs) remain unpredictable, and robust biomarkers are still lacking. Recent studies have shown that tumors present somatic molecular alterations related to better treatment response, and it is also clear that tumor-associated bacteria are modulators of chemotherapy and immunotherapy efficacy, therefore having implications for long-term survivorship and a good potential as the biomarkers of outcome. Here, we performed whole exome sequencing and 16S ribosomal RNA (rRNA) amplicon sequencing from 44 pre-treatment LARC biopsies from Argentinian and Brazilian patients, treated with neoadjuvant chemoradiotherapy or total neoadjuvant treatment, searching for predictive biomarkers of response (responders, n = 17; non-responders, n = 27). In general, the somatic landscape of LARC was not capable to predict a response; however, a significant enrichment in mutational signature SBS5 was observed in non-responders (p = 0.0021), as well as the co-occurrence of APC and FAT4 mutations (p < 0.05). Microbiota studies revealed a similar alpha and beta diversity of bacteria between response groups. Yet, the linear discriminant analysis (LDA) of effect size indicated an enrichment of Hungatella, Flavonifractor, and Methanosphaera (LDA score ≥3) in the pre-treatment biopsies of responders, while non-responders had a higher abundance of Enhydrobacter, Paraprevotella (LDA score ≥3) and Finegoldia (LDA score ≥4). Altogether, the evaluation of these biomarkers in pre-treatment biopsies could eventually predict a neoadjuvant treatment response, while in post-treatment samples, it could help in guiding non-operative treatment strategies.

7.
Genes (Basel) ; 13(2)2022 01 27.
Artículo en Inglés | MEDLINE | ID: mdl-35205282

RESUMEN

Whereas targeted and shotgun sequencing approaches are both powerful in allowing the study of tissue-associated microbiota, the human: microorganism abundance ratios in tissues of interest will ultimately determine the most suitable sequencing approach. In addition, it is possible that the knowledge of the relative abundance of bacteria and fungi during a treatment course or in pathological conditions can be relevant in many medical conditions. Here, we present a qPCR-targeted approach to determine the absolute and relative amounts of bacteria and fungi and demonstrate their relative DNA abundance in nine different human tissue types for a total of 87 samples. In these tissues, fungi genomes are more abundant in stool and skin samples but have much lower levels in other tissues. Bacteria genomes prevail in stool, skin, oral swabs, saliva, and gastric fluids. These findings were confirmed by shotgun sequencing for stool and gastric fluids. This approach may contribute to a more comprehensive view of the human microbiota in targeted studies for assessing the abundance levels of microorganisms during disease treatment/progression and to indicate the most informative methods for studying microbial composition (shotgun versus targeted sequencing) for various samples types.


Asunto(s)
Bacterias , Metagenómica , Bacterias/genética , ADN de Hongos , Hongos/genética , Humanos , Metagenómica/métodos , Análisis de Secuencia de ADN
8.
Acta Paul. Enferm. (Online) ; 35: eAPE0384345, 2022. tab, graf
Artículo en Portugués | LILACS, BDENF - Enfermería | ID: biblio-1374031

RESUMEN

Resumo Objetivo Avaliar o estado emocional, nas dimensões ansiedade e depressão, e a qualidade de vida, em pessoas com artrite reumatóide. Métodos Estudo primário, descritivo e transversal, desenvolvido na região norte de Portugal, com uma amostra de 139 pessoas com artrite reumatóide (79,86% mulheres) e com média de idades de 63.05 anos. Foram aplicados: um questionário sociodemográfico, a escala "Hospital Anxiety and Depression Scale" e o questionário "EQ-5D - Avaliação de Ganhos em Saúde". Na análise de dados, por meio do programa IBM Statistical Package for the Social Sciences (SPSS) Statistics 24 , recorreu-se à estatística inferencial, considerando-se estatisticamente significativo um p < 0,05. Resultados Os achados sobre o estado emocional mostraram níveis de ansiedade severos em 45,3%, ansiedade moderada em 36,7%, ansiedade leve em 10,1% e apenas 7,9% dos participantes pontuaram sem ansiedade. A maioria não apresenta sintomatologia depressiva (71,9%) e 13,7% manifestou depressão leve. Os baixos níveis de depressão foram associados a uma melhor qualidade-de-vida, contrariamente aos níveis de ansiedade, onde uma diminuição dos mesmos diminui a qualidade-de-vida (p=0,000). Conclusão Observou-se que a ansiedade e a depressão emergiram como preditores da QDV em pessoas com AR. Para proteger e melhorar a saúde dos pacientes, destaca-se a necessidade de implementar intervenções de enfermagem direcionadas ao controle dos fatores que induzem comportamentos ansiogênicos e depressivos.


Resumen Objetivo Evaluar el estado emocional, en las dimensiones ansiedad y depresión, y la calidad de vida, en personas con artritis reumatoide. Métodos Estudio primario, descriptivo y transversal, desarrollado en la región norte de Portugal, con una muestra de 139 personas con artritis reumatoide (79,86 % mujeres) con un promedio de edad de 63.05 años. Se aplicaron: un cuestionario sociodemográfico, la escala "Hospital Anxiety and Depression Scale" y el cuestionario "EQ-5D - Avaliação de Ganhos em Saúde". En el análisis de datos, por medio del programa IBM Statistical Package for the Social Sciences (SPSS) Statistics 24 , se recorrió a la estadística inferencial, y se consideró estadísticamente significante un p < 0,05. Resultados Los hallazgos sobre el estado emocional mostraron niveles de ansiedad severos en 45,3 %, ansiedad moderada en 36,7 %, ansiedad leve en 10,1 % y apenas el 7,9 % de los participantes puntuaron sin ansiedad. La mayoría no presenta sintomatología depresiva (71,9 %) y el 13,7 % manifestó depresión leve. Los bajos niveles de depresión estuvieron asociados a una mejor calidad de vida, contrariamente a los niveles de ansiedad, en la que una disminución en ellos disminuyó la calidad de vida (p=0,000). Conclusión Se observó que la ansiedad y la depresión emergieron como predictores de la CDV en personas con AR. Para proteger y mejorar la salud de los pacientes, se destaca la necesidad de implementar intervenciones de enfermería direccionadas al control de los factores que inducen a comportamientos ansiogénicos y depresivos.


Abstract Objective To assess the emotional states of the anxiety and depression dimensions and the quality of life in patients with rheumatoid arthritis. Methods A primary, descriptive, and cross-sectional study conducted in the northern region of Portugal, using a sample of 139 people suffering from rheumatoid arthritis (79.86% of whom were women) with a mean age of 63.05 years. A sociodemographic questionnaire, the "Hospital Anxiety and Depression Scale" and the "EQ-5D - Health Gains questionnaire were administered. Inferential statistics were used to conduct data analysis. IBM Statistical Package for the Social Sciences (SPSS) Statistics 24 program was the instrument of choice and p < 0.05 was deemed statistically significant. Results Findings on emotional state showed severe/extreme anxiety levels in 45.3% of the respondents, moderate anxiety in 36.7% of them, mild anxiety in 10.1% and only 7.9% of participants showed no sign of anxiety. Most of the participants did not present any sort of depressive symptoms (71.9%) and 13.7% of them were diagnosed with mild depression. Low levels of depression were associated with a better quality of life. On the other hand, low levels of anxiety see to lead to poorer quality of life (p=0.000). Conclusion Evidence shows that anxiety and depression are predictors of QOL in patients with RA. That way, nursing interventions aimed at controlling the factors that trigger anxiogenic and depressive behaviours must be implemented to protect and improve patients' health.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Ansiedad , Artritis Reumatoide , Calidad de Vida/psicología , Depresión , Estudios Transversales
9.
J Mol Diagn ; 23(9): 1127-1137, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34186175

RESUMEN

About 4% to 7% of the non-small-cell lung cancer patients have anaplastic lymphoma kinase (ALK) rearrangements, and specific targeted therapies improve patients' outcomes significantly. ALK gene fusions are detected by immunohistochemistry or fluorescent in situ hybridization as gold standards in South America. Next-generation sequencing-based assays are a reliable alternative, able to perform simultaneous detection of multiple events from a single sample. We analyzed 4240 non-small-cell lung cancer samples collected in 37 hospitals from Chile, Brazil, and Peru, where ALK rearrangements were determined as part of their standard of care (SofC) using either immunohistochemistry or fluorescent in situ hybridization. A subset of 1450 samples was sequenced with the Oncomine Focus Assay (OFA), and the concordance with the SofC tests was measured. An orthogonal analysis was performed using a real-time quantitative PCR echinoderm microtubule-associated protein-like 4-ALK fusion detection kit. ALK fusion prevalence is similar for Chile (3.67%; N = 2142), Brazil (4.05%; N = 1013), and Peru (4.59%; N = 675). Although a comparison between OFA and SofC assays showed similar sensitivity, OFA had significantly higher specificity and higher positive predictive value, which opens new opportunities for a more specific determination of ALK gene rearrangements.


Asunto(s)
Quinasa de Linfoma Anaplásico/genética , Carcinoma de Pulmón de Células no Pequeñas/genética , Fusión Génica , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Neoplasias Pulmonares/genética , Proteínas de Fusión Oncogénica/genética , Adulto , Anciano , Anciano de 80 o más Años , Brasil/epidemiología , Carcinoma de Pulmón de Células no Pequeñas/epidemiología , Chile/epidemiología , Femenino , Reordenamiento Génico , Humanos , Inmunohistoquímica/métodos , Hibridación Fluorescente in Situ/métodos , Neoplasias Pulmonares/epidemiología , Masculino , Persona de Mediana Edad , Perú/epidemiología , Estudios Prospectivos , Estudios Retrospectivos , Nivel de Atención , Adulto Joven
10.
Cancers (Basel) ; 13(3)2021 Jan 27.
Artículo en Inglés | MEDLINE | ID: mdl-33513945

RESUMEN

DNA mismatch repair deficiency (dMMR) is associated with the microsatellite instability (MSI) phenotype and leads to increased mutation load, which in turn may impact anti-tumor immune responses and treatment effectiveness. Various mutational signatures directly linked to dMMR have been described for primary cancers. To investigate which mutational signatures are associated with prognosis in gastric cancer, we performed a de novo extraction of mutational signatures in a cohort of 787 patients. We detected three dMMR-related signatures, one of which clearly discriminates tumors with MLH1 gene silencing caused by promoter hypermethylation (area under the curve = 98%). We then demonstrated that samples with the highest exposure of this signature share features related to better prognosis, encompassing clinical and molecular aspects and altered immune infiltrate composition. Overall, the assessment of the prognostic value and of the impact of modifications in MMR-related genes on shaping specific dMMR mutational signatures provides evidence that classification based on mutational signature exposure enables prognosis stratification.

11.
Cancers (Basel) ; 12(12)2020 Dec 09.
Artículo en Inglés | MEDLINE | ID: mdl-33316873

RESUMEN

DNA repair deficiency (DRD) is an important driver of carcinogenesis and an efficient target for anti-tumor therapies to improve patient survival. Thus, detection of DRD in tumors is paramount. Currently, determination of DRD in tumors is dependent on wet-lab assays. Here we describe an efficient machine learning algorithm which can predict DRD from histopathological images. The utility of this algorithm is demonstrated with data obtained from 1445 cancer patients. Our method performs rather well when trained on breast cancer specimens with homologous recombination deficiency (HRD), AUC (area under curve) = 0.80. Results for an independent breast cancer cohort achieved an AUC = 0.70. The utility of our method was further shown by considering the detection of mismatch repair deficiency (MMRD) in gastric cancer, yielding an AUC = 0.81. Our results demonstrate the capacity of our learning-base system as a low-cost tool for DRD detection.

12.
Pediatr. (Asunción) ; 47(2)ago. 2020.
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1386626

RESUMEN

RESUMEN En noviembre del 2019 inicia en Wuhan, lo que sería una nueva pandemia, por un coronavirus que no había sido identificado previamente, el SARS-CoV-2. Posteriormente fue reportado en Paraguay el primer caso de covid-19 en marzo del 2020. A pesar de que se trata de un virus de manifestación preferentemente respiratoria, sabemos hasta la fecha que pueden presentar otros síntomas, incluso ser totalmente asintomáticos. Se ha visto que las lesiones en piel, al igual que en muchas otras enfermedades infecciosas, también son causadas por este nuevo virus, por lo que el dermatólogo juega un rol importante en esta batalla. Reportamos el primer caso registrado por el servicio de Dermatología del Hospital Nacional de Itaugua, de manifestaciones cutáneas en un lactante, secundarias a la enfermedad de COVID-19.


ABSTRACT In November 2019, in Wuhan, China, what would be a new pandemic started, due to a coronavirus that had not been previously identified, SARS-CoV-2. Subsequently, the first case of COVID-19 was reported in Paraguay in March 2020. Despite the fact that it is a virus of preferential respiratory manifestation, we know to date that it can present with other symptoms, including asymptomatically. Skin lesions, like in many other infectious diseases, have been shown to be caused by this new virus as well, making the dermatologist play an important role in this battle. We report the first case registered by the Dermatology service of the Itaugua National Hospital of cutaneous manifestations in an infant, secondary to COVID-19 disease.

13.
Genet Mol Biol ; 43(2): e20180351, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32352476

RESUMEN

Next-generation sequencing (NGS) platforms allow the analysis of hundreds of millions of molecules in a single sequencing run, revolutionizing many research areas. NGS-based microRNA studies enable expression quantification in unprecedented scale without the limitations of closed-platforms. Yet, whereas a massive amount of data produced by these platforms is available, comparisons of quantification/discovery capabilities between platforms are still lacking. Here we compare two NGS-platforms: SOLiD and PGM, by evaluating their microRNA identification/quantification capabilities using two breast-derived cell-lines. A high expression correlation (R2 > 0.9) was achieved, encompassing 97% of the miRNAs, and the few discrepancies in miRNA counts were attributable to molecules that have very low expression. Quantification divergences indicative of artefactual representation were seen for 14 miRNAs (higher in SOLiD-reads) and another 10 miRNAs more abundant in PGM-data. An inspection of these revealed an increased and statistically significant count of uracyls and uracyl-stretches for PGM-enriched miRNAs, compared to SOLiD and to the miRBase. In parallel, adenines and adenine-stretches were enriched for SOLiDderived miRNA reads. We conclude that, whereas both platforms are overall consistent and can be used interchangeably for microRNA expression studies, particular sequence features appear to be indicative of specific platform bias, and their presence in microRNAs should be considered for database-analyses.

14.
Methods Enzymol ; 645: 141-154, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33565968

RESUMEN

Extracellular vesicles (EVs) have been recognized as relevant players in cell-cell communication. To fully explore their potential as carriers of biological information in clinical settings, protocols capable of dealing with minute amounts of proteins, lipids, and nucleic acids present in their cargo are a requirement. Here we delve into a protocol to decipher the total transcriptome of EVs, from undetectable amounts of EVs-derived RNA from clinical samples.


Asunto(s)
Vesículas Extracelulares , Comunicación Celular , Proteínas , ARN/genética , Transcriptoma
15.
Int J Cancer ; 146(1): 181-191, 2020 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31090066

RESUMEN

Mechanisms of viral oncogenesis are diverse and include the off-target activity of enzymes expressed by the infected cells, which evolved to target viral genomes for controlling their infection. Among these enzymes, the single-strand DNA editing capability of APOBECs represent a well-conserved viral infection response that can also cause untoward mutations in the host DNA. Here we show, after evaluating somatic single-nucleotide variations and transcriptome data in 240 gastric cancer samples, a positive correlation between APOBEC3s mRNA-expression and the APOBEC-mutation signature, both increased in EBV+ tumors. The correlation was reinforced by the observation of APOBEC mutations preferentially occurring in the genomic loci of the most active transcripts. This EBV infection and APOBEC3 mutation-signature axis were confirmed in a validation cohort of 112 gastric cancer patients. Our findings suggest that APOBEC3 upregulation in EBV+ cancer may boost the mutation load, providing further clues to the mechanisms of EBV-induced gastric carcinogenesis. After further validation, this EBV-APOBEC axis may prove to be a secondary driving force in the mutational evolution of EBV+ gastric tumors, whose consequences in terms of prognosis and treatment implications should be vetted.


Asunto(s)
Citidina Desaminasa/genética , ADN de Neoplasias/genética , Herpesvirus Humano 4/patogenicidad , Neoplasias Gástricas/virología , Desaminasas APOBEC , Carcinogénesis , Genes Virales , Herpesvirus Humano 4/genética , Humanos , Mutación , Neoplasias Gástricas/patología
16.
PLoS Genet ; 15(12): e1008482, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31846472

RESUMEN

The specific genes and molecules that drive physiological angiogenesis differ from those involved in pathological angiogenesis, suggesting distinct mechanisms for these seemingly related processes. Unveiling genes and pathways preferentially associated with pathologic angiogenesis is key to understanding its mechanisms, thereby facilitating development of novel approaches to managing angiogenesis-dependent diseases. To better understand these different processes, we elucidated the transcriptome of the mouse retina in the well-accepted oxygen-induced retinopathy (OIR) model of pathological angiogenesis. We identified 153 genes changed between normal and OIR retinas, which represent a molecular signature relevant to other angiogenesis-dependent processes such as cancer. These genes robustly predict the survival of breast cancer patients, which was validated in an independent 1,000-patient test cohort (40% difference in 15-year survival; p = 2.56 x 10-21). These results suggest that the OIR model reveals key genes involved in pathological angiogenesis, and these may find important applications in stratifying tumors for treatment intensification or for angiogenesis-targeted therapies.


Asunto(s)
Neoplasias de la Mama/genética , Perfilación de la Expresión Génica/métodos , Neovascularización Patológica/genética , Oxígeno/efectos adversos , Retina/química , Anciano , Animales , Neoplasias de la Mama/mortalidad , Modelos Animales de Enfermedad , Femenino , Regulación Neoplásica de la Expresión Génica , Redes Reguladoras de Genes , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Ratones , Persona de Mediana Edad , Neovascularización Patológica/inducido químicamente , Neovascularización Patológica/mortalidad , Retina/efectos de los fármacos , Análisis de Secuencia de ARN
17.
Eur J Clin Microbiol Infect Dis ; 38(9): 1591-1597, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31114971

RESUMEN

Despite being one of the most studied cancer-related infections, the relationship between Helicobacter pylori infection and gastric adenocarcinoma (GC) remains, in some points, obscure. Based on a critical analysis of the available literature regarding stomach microbiota, we aimed to shed light to a possible new interpretation of the current understanding about the Helicobacter pylori-related GC carcinogenesis. We analyzed data from the literature on Helicobacter pylori and other potential carcinogenic pathogens, in both benignant conditions and gastric adenocarcinoma. Helicobacter pylori is the dominant microorganism in benignant conditions as non-complicated gastritis. In atrophic gastritis, metaplasia and, mainly, in gastric adenocarcinoma, a strong reduction in Helicobacter pylori abundance, and increased occurrence of other microorganisms is strongly demonstrated by metagenomic experiments. While causing peptic disease and keeping the stomach's high acidity, Helicobacter pylori infection avoids gastric infection by carcinogenic intestinal microbiota. Nevertheless, Helicobacter pylori persistence may also provoke an atrophic gastritis, a condition that causes its own decline, due to a microenvironment modification, including reduced acidity, resulting in Helicobacter pylori substitution by a cancer-prone microbiota. This new interpretation might result in a dramatic modification on clinical management of Helicobacter pylori-related gastric disease.


Asunto(s)
Carcinogénesis , Disbiosis , Gastritis/microbiología , Microbioma Gastrointestinal , Infecciones por Helicobacter/microbiología , Helicobacter pylori/patogenicidad , Neoplasias Gástricas/microbiología , Gastritis Atrófica/microbiología , Humanos , Estómago/microbiología , Microambiente Tumoral
18.
Pharmacogenomics ; 20(7): 493-502, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-31124410

RESUMEN

HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.


Asunto(s)
Neoplasias de la Mama/genética , MicroARNs/genética , ARN Circular/genética , Receptor ErbB-2/genética , Neoplasias de la Mama/patología , Línea Celular Tumoral , Femenino , Regulación Neoplásica de la Expresión Génica/genética , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Recurrencia Local de Neoplasia/genética , Recurrencia Local de Neoplasia/patología , Transcriptoma/genética
19.
Oncologist ; 24(9): e854-e863, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-30846515

RESUMEN

BACKGROUND: Gastric adenocarcinoma (GAC) is the third deadliest malignant neoplasm worldwide, mostly because of late disease diagnosis, low chemotherapy response rates, and an overall lack of tumor biology understanding. Therefore, tools for prognosis and prediction of treatment response are needed. Quantification of circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) and their expression of biomarkers has potential clinical relevance. Our aim was to evaluate CTCs and CTM and their expression of HER2 and plakoglobin in patients with nonmetastatic GAC, correlating the findings to clinicopathological data. MATERIALS AND METHODS: CTC enrichment was performed with isolation by size of epithelial tumor cells, and the analysis was performed with immunocytochemistry and microscopy. Two collections were made: one at diagnosis (55 samples before neoadjuvant treatment) and one after surgery and before adjuvant therapy (33 samples). RESULTS: A high detection rate of CTCs (90%) was observed at baseline. We evaluated HER2 expression in 45/55 biopsy samples and in 42/55 CTC samples, with an overlap of 36 subjects. Besides the good agreement observed for HER2 expression in primary tumors and paired CTCs for 36 cases (69.4%; κ = 0.272), the analysis of HER2 in CTCs showed higher positivity (43%) compared with primary tumors (11%); 3/5 patients with disease progression had HER2-negative primary tumors but HER2-positive CTCs. A significant CTC count drop in follow-up was seen for CTC-HER2-positive cases (4.45 to 1.0 CTCs per mL) compared with CTC-HER2-negative cases (2.6 to 1.0 CTCs per mL). The same was observed for CTC-plakoglobin-positive cases (2.9 to 1.25 CTCs per mL). CONCLUSION: CTC analysis, including their levels, plakoglobin, and HER2 expression, appears to be a promising tool in the understanding the biology and prognosis of GAC. IMPLICATIONS FOR PRACTICE: The analysis of circulating tumor cell levels from the blood of patients with gastric adenocarcinoma, before and after neoadjuvant treatment, is useful to better understand the behavior of the disease as well as the patients more likely to respond to treatment.


Asunto(s)
Embolia/patología , Células Neoplásicas Circulantes/patología , Neoplasias Gástricas/patología , Adenocarcinoma/sangre , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Biomarcadores de Tumor/sangre , Embolia/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Células Neoplásicas Circulantes/metabolismo , Pronóstico , Receptor ErbB-2/metabolismo , Neoplasias Gástricas/sangre , Neoplasias Gástricas/cirugía , Tasa de Supervivencia
20.
Int J Cancer ; 145(4): 1090-1098, 2019 08 15.
Artículo en Inglés | MEDLINE | ID: mdl-30779121

RESUMEN

Whereas cancer patients have benefited from liquid biopsies, the scenario for gastric adenocarcinoma (GAC) is still dismal. We used next-generation deep sequencing of TP53-a highly mutated and informative gene in GAC-to assess mutations in tumor biopsies, plasma (PL) and stomach fluids (gastric wash-GW). We evaluated their potential to reveal tumor-derived mutations, useful for monitoring mutational dynamics at diagnosis, progression and treatment. Exon-capture libraries were constructed from 46 patients including tumor biopsies, GW and PL pre and post-treatment (196 samples), with high vertical coverage >8,000×. At diagnosis, we detected TP53 mutations in 15/46 biopsies (32.6%), 7/46 GW- (15.2%) and 6/46 PL-samples (13%). Biopsies and GW were concordant in 38/46 cases (82.6%) for the presence/absence of mutations and, furthermore, four GW-exclusive mutations were identified, suggesting tumor heterogeneity. Considering the combined analysis of GW and PL, TP53 mutations found in biopsies were also identified in 9/15 (60%) of cases, the highest detection level reported for GAC. Our study indicates that GW could be useful to track DNA alterations, especially if anchored to a comprehensive gene-panel designed for this malignancy.


Asunto(s)
Adenocarcinoma/genética , Adenocarcinoma/patología , Mutación/genética , Neoplasias Gástricas/genética , Neoplasias Gástricas/patología , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/genética , Análisis Mutacional de ADN/métodos , Femenino , Estudios de Seguimiento , Humanos , Biopsia Líquida/métodos , Masculino , Persona de Mediana Edad , Estómago/patología , Proteína p53 Supresora de Tumor/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA